MYCN and neuroblastoma: Patients without MYCN or 12q24.31 amplification had the best prognosis, patients with the gain of 12q24.31 region had an intermediate prognosis, and patients with MYCN-amplified neuroblastomas had the worst prognosis (Figure 4).